AU2021389409A1 - Medicine for alleviating neuropathic pain - Google Patents

Medicine for alleviating neuropathic pain Download PDF

Info

Publication number
AU2021389409A1
AU2021389409A1 AU2021389409A AU2021389409A AU2021389409A1 AU 2021389409 A1 AU2021389409 A1 AU 2021389409A1 AU 2021389409 A AU2021389409 A AU 2021389409A AU 2021389409 A AU2021389409 A AU 2021389409A AU 2021389409 A1 AU2021389409 A1 AU 2021389409A1
Authority
AU
Australia
Prior art keywords
receptor
pain
compound
hydroxymethyl
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021389409A
Other languages
English (en)
Inventor
Yosuke Imai
Hikaru Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Publication of AU2021389409A1 publication Critical patent/AU2021389409A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021389409A 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain Abandoned AU2021389409A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-199206 2020-11-30
JP2020199206 2020-11-30
PCT/JP2021/043375 WO2022114122A1 (ja) 2020-11-30 2021-11-26 神経障害性疼痛を緩和させるための医薬

Publications (1)

Publication Number Publication Date
AU2021389409A1 true AU2021389409A1 (en) 2023-06-22

Family

ID=81755628

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021389409A Abandoned AU2021389409A1 (en) 2020-11-30 2021-11-26 Medicine for alleviating neuropathic pain

Country Status (11)

Country Link
US (1) US20240009180A1 (https=)
EP (1) EP4272758A4 (https=)
JP (1) JPWO2022114122A1 (https=)
KR (1) KR20230096055A (https=)
CN (1) CN116782901A (https=)
AU (1) AU2021389409A1 (https=)
CA (1) CA3198258A1 (https=)
IL (1) IL302972A (https=)
MX (1) MX2023006289A (https=)
TW (1) TW202237111A (https=)
WO (1) WO2022114122A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121159455A (zh) * 2024-06-18 2025-12-19 武汉人福创新药物研发中心有限公司 氨基酯类化合物及其作为p2x7拮抗剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013269606B2 (en) 2012-06-01 2018-05-17 Ablynx N.V. P2X7 receptor antagonists and agonists
JP6301920B2 (ja) 2013-05-27 2018-03-28 国立大学法人 岡山大学 疼痛治療薬
US11077100B2 (en) * 2017-03-13 2021-08-03 Raqualia Pharma Inc. Tetrahydroquinoline derivatives as P2X7 receptor antagonists
EP3398941A1 (en) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterocyclic p2x7 antagonists
JP7311944B2 (ja) 2018-04-16 2023-07-20 塩野義製薬株式会社 二環性含窒素複素環誘導体を含有する医薬組成物
JP2019182806A (ja) 2018-04-16 2019-10-24 塩野義製薬株式会社 二環性複素環誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
CN116782901A (zh) 2023-09-19
WO2022114122A1 (ja) 2022-06-02
US20240009180A1 (en) 2024-01-11
KR20230096055A (ko) 2023-06-29
EP4272758A1 (en) 2023-11-08
EP4272758A4 (en) 2025-01-29
JPWO2022114122A1 (https=) 2022-06-02
CA3198258A1 (en) 2022-06-02
IL302972A (en) 2023-07-01
MX2023006289A (es) 2023-07-31
TW202237111A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
Bonaventure et al. Selective blockade of 5-hydroxytryptamine (5-HT) 7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents
Thomas et al. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications
US20110306654A1 (en) Methods for identifying analgesic agents
KR20100127799A (ko) 세로토닌 운반체 유전자 및 알콜중독의 치료
US20180066314A1 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia
WO2022105665A1 (zh) 一种预防、治疗疼痛、炎症的化合物及其应用
AU2021389409A1 (en) Medicine for alleviating neuropathic pain
US20100260772A1 (en) Methods for treating or preventing diseases associated with low bone mass
US11779588B2 (en) Method of treating amyotrophic lateral sclerosis
EP3156054A1 (en) Medicine for preventing and/or treating stress-induced diseases
JP7088628B2 (ja) うつ病や急性ストレス障害の診断バイオマーカー及び治療又は予防用組成物
HK40094114A (en) Medicine for alleviating neuropathic pain
US20250381197A1 (en) Regimen for Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment
JP2024543347A (ja) 筋萎縮性側索硬化症を治療する方法およびそれに対する投与計画
Qi et al. Discovery of novel oxindole derivatives as TRPA1 antagonists with potent analgesic activity for pain treatment
JP7838764B2 (ja) 新型コロナウイルス感染症後遺症の治療薬
EP3233825B1 (en) Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
Smith Muscarinic Acetylcholine Receptor 1: Implications for Precision Medicine and Rett Syndrome Therapeutics
EP1465609A2 (en) Modulation of dopaminergic neurons
Nelson et al. Mouse models of non-dystrophic and dystrophic myotonia exhibit nociplastic pain-like behaviors
Meng et al. 109P Preserve sense by antisense–a novel allele-specific antisense oligonucleotide therapy for SPTLC1-related hereditary sensory neuropathy
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
US20200352950A1 (en) Novel method of treating dystonia
WO2023078807A1 (en) A class iia hdac inhibitor and decitabine to treat myopathy
JP2024537981A (ja) 筋萎縮性側索硬化症を治療する方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted